Shire (NASDAQ:SHPG) has been assigned a consensus rating of “Buy” from the twenty-one ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $208.89.
Several research firms have recently weighed in on SHPG. Kepler Capital Markets reaffirmed a “buy” rating on shares of Shire in a report on Friday, May 11th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Shire in a report on Tuesday, May 8th. ValuEngine lowered shares of Shire from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. BTIG Research reaffirmed a “buy” rating and set a $195.00 price objective on shares of Shire in a report on Sunday, April 29th. Finally, SunTrust Banks lowered their price target on shares of Shire to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 20th.
Several institutional investors have recently modified their holdings of SHPG. Boston Partners increased its holdings in shares of Shire by 60.9% in the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock valued at $363,351,000 after purchasing an additional 886,572 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in Shire in the first quarter valued at approximately $113,097,000. ING Groep NV boosted its stake in Shire by 9,043.1% in the fourth quarter. ING Groep NV now owns 524,537 shares of the biopharmaceutical company’s stock valued at $81,366,000 after acquiring an additional 518,800 shares during the last quarter. FNY Partners Fund LP boosted its stake in Shire by 346.6% in the fourth quarter. FNY Partners Fund LP now owns 474,460 shares of the biopharmaceutical company’s stock valued at $73,598,000 after acquiring an additional 368,214 shares during the last quarter. Finally, Brandywine Global Investment Management LLC bought a new position in Shire in the fourth quarter valued at approximately $41,763,000. 18.12% of the stock is owned by institutional investors and hedge funds.
Shire opened at $169.89 on Friday, according to Marketbeat Ratings. The company has a market cap of $51.35 billion, a PE ratio of 11.21, a PEG ratio of 1.33 and a beta of 1.30. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.14 and a quick ratio of 0.66. Shire has a 1-year low of $123.73 and a 1-year high of $187.58.
Shire (NASDAQ:SHPG) last posted its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $3.86 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.58 by $0.28. The company had revenue of $3.77 billion during the quarter. Shire had a net margin of 28.96% and a return on equity of 13.60%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business posted $3.63 EPS. equities analysts predict that Shire will post 15.26 earnings per share for the current year.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.